PL433150A1 - Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level - Google Patents

Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level

Info

Publication number
PL433150A1
PL433150A1 PL433150A PL43315020A PL433150A1 PL 433150 A1 PL433150 A1 PL 433150A1 PL 433150 A PL433150 A PL 433150A PL 43315020 A PL43315020 A PL 43315020A PL 433150 A1 PL433150 A1 PL 433150A1
Authority
PL
Poland
Prior art keywords
risk
determining
blood lead
cancers
women
Prior art date
Application number
PL433150A
Other languages
Polish (pl)
Inventor
Jan LUBIŃSKI
Anna Jakubowska
Wojciech MARCINIAK
Róża Derkacz
Katarzyna Białkowska
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL433150A priority Critical patent/PL433150A1/en
Publication of PL433150A1 publication Critical patent/PL433150A1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka raka, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia ołowiu we krwi pełnej osoby badanej, przy czym stężenie wskazuje na dwukrotnie obniżone ryzyko rozwoju raka w przypadku występowania wartości stężenia ołowiu we krwi poniżej 9,13 µg/l.The subject of the application is a method of determining cancer risk, characterized in that it includes a quantitative assessment of the whole blood lead concentration of a test subject, the concentration showing a doubled risk of developing cancer when blood lead values are below 9.13 µg / L.

PL433150A 2020-03-05 2020-03-05 Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level PL433150A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL433150A PL433150A1 (en) 2020-03-05 2020-03-05 Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433150A PL433150A1 (en) 2020-03-05 2020-03-05 Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level

Publications (1)

Publication Number Publication Date
PL433150A1 true PL433150A1 (en) 2021-09-06

Family

ID=77662599

Family Applications (1)

Application Number Title Priority Date Filing Date
PL433150A PL433150A1 (en) 2020-03-05 2020-03-05 Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level

Country Status (1)

Country Link
PL (1) PL433150A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446899A1 (en) * 2023-11-29 2025-06-02 Read-Gene Spółka Akcyjna Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446899A1 (en) * 2023-11-29 2025-06-02 Read-Gene Spółka Akcyjna Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration

Similar Documents

Publication Publication Date Title
van Leeuwen et al. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment
Abdollah et al. Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis.
Landercasper et al. A reappraisal of the comparative effectiveness of lumpectomy versus mastectomy on breast cancer survival: a propensity score–matched update from the National Cancer Data Base (NCDB)
Leone et al. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis
BR112019001384A2 (en) colorectal cancer combination test
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
Castelo et al. Comparing Observation, Axillary Radiotherapy, and Completion Axillary Lymph Node Dissection for Management of Axilla in Breast Cancer in Patients with Positive Sentinel Nodes: A Systematic Review: M. Castelo et al.
Cooper et al. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database
EP4294455A4 (en) USE OF AN ANTIBODY CONJUGATE AGENT AGENT AGENT IN THE TREATMENT OF SPECIFIC BREAST CANCER
PL437046A1 (en) Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
Regis et al. Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness
Mendoza et al. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital
Ganjoo et al. The treatment outcome for adult patients with Ewing’s sarcoma
Ayala de la Peña et al. Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
Jueckstock et al. Adjuvant therapeutic decisions in elderly breast cancer patients: the role of chemotherapy in a retrospective analysis
Elkerdany et al. Serum 25-hydroxyvitamin D levels in relation to disease status and prognosis in acute myeloid leukemia
PL439317A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood of women who are carriers of the most common BRCA1 and BRCA2 gene mutations
Son et al. Analysis of clinical factors for the determination of optimal serum level of thyrotropin after recombinant human thyroid-stimulating hormone administration
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women
EA202190671A1 (en) IMMUNOGENETIC SCREENING TEST FOR CANCER
PL438038A1 (en) Method of determining risk of cancer in women depending on age, history of smoking and selenium concentration in the blood
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL439314A1 (en) Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood